Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis

Philipp Schuetz, Mirjam Christ-Crain, Nils G Morgenthaler, Joachim Struck, Andreas Bergmann, Beat Müller, Philipp Schuetz, Mirjam Christ-Crain, Nils G Morgenthaler, Joachim Struck, Andreas Bergmann, Beat Müller

Abstract

Plasma levels of endothelin-1 (ET-1) and adrenomedullin (ADM), two opposingly acting peptides, correlate with mortality in endotoxemia, but their measurement is cumbersome. New sandwich assays have been introduced that measure more stable precursor fragments. The objective of this study was to investigate the counterplay of their precursor peptides in septic patients and to compare them with disease severity and other biomarkers. Blood samples of an observational study in 95 consecutive critically ill patients admitted to the intensive care unit (ICU) were analyzed. CT-proET-1 and MR-proADM concentrations on admission were measured using new sandwich immunoassays. Depending on the clinical severity of the infection, both CT-proET-1 and MR-proADM levels exhibited a gradual increase from Systemic Inflammatory Response Syndrome (SIRS) to sepsis and septic shock (p < .001). Compared to the group of survivors, the group of nonsurvivors had higher median values of MR-proADM (5.7 nmol/L [range 0.4 to 21.0] versus 1.9 nmol/L [range 0.3 to 17.1], p < .02) and similar CT-proET-1 levels (56.0pmol/L [range 0.5 to 271.0] versus 54.1pmol/L [range 1.0 to 506.0], p = .86). Receiver operating characteristics (ROC) curve analysis showed a higher prognostic accuracy of the calculated ratio of both counteracting substances as compared to CT-proET-1 (p = 0.001) and C-reactive protein (CRP) (p = .001) and in the range of MR-proADM (p = .51), procalcitonin (p = 0.22), and the APACHE II score (p = .61). Endothelin-1 and adrenomedullin precursor peptides gradually increase with increasing severities of infection in critically ill patients. The ratio of the two counteracting peptides correlates with mortality and shows a prognostic accuracy to predict adverse outcome comparable to the APACHE II score.

Figures

FIG. 1.
FIG. 1.
CT-proET-1 and MR-proADM values in all patients according to the severity of disease. Patients' data on admission to the ICU were grouped according to the severity of the disease following consensus criteria in groups with “SIRS, but no sepsis,” “sepsis,” and “septic shock.” Squares denote median values and whiskers indicate 25th and 75th percentiles.
FIG. 2.
FIG. 2.
CT-proET-1-, MR-proADM, and the calculated ratio in surviving as compared to nonsurviving patients. Data from all patients on admission are shown. Squares denote median values, boxes represent 25th to 75th percentiles and whiskers indicate the range.
FIG. 3.
FIG. 3.
Receiver operating curve (ROC) analysis of CT-proET1, MRproADM, the CT-proET1/MR-proADM ratio and the APACHE II score with respect to outcome prediction of critically ill patients. Receiver operating characteristic (ROC) plots are graphical plots illustrating the sensitivity (y-axis) and the specificity (x -axis) for all cut-off points of a diagnostic or prognostic test. The overall performance and a summary measure of the diagnostic accuracy of a test can be expressed as the area under the ROC curve (AUC). Note that an AUCof 0.50 means that the diagnostic accuracy in question is equivalent to that which would be obtained by flipping a coin (i.e., random chance). (a) Data of all patients (n = 95) with SIRS and sepsis on admission to the ICU. Sensitivity was calculated with nonsurvivors (n = 21), specificity with survivors (n = 74) during their hospital stay. (b) Data of patients with sepsis (including septic shock) in need for blood pressure support with vasoactiva (n = 30) on admission to the ICU. Sensitivity was calculated with nonsurvivors (n = 9), specificity with survivors (n = 21) during their hospital stay.

References

    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine. 1992;20:864–874.
    1. Abraham E., Laterre P.F., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine. 2005;353:1332–1341.
    1. Bone R.C., Balk R.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655.
    1. Booth F.V., Short M., et al. Application of a population-based severity scoring system to individual patients results in frequent misclassification. Critical Care. 2005;9:R522–R529.
    1. Brauner J.S., Rohde L.E., et al. Circulating endothelin-1 and tumor necrosis factor-alpha: Early predictors of mortality in patients with septic shock. Intensive Care Medicine. 2000;26:305–313.
    1. Christ-Crain M., Morgenthaler NG., et al. Mid-regional proadrenomedullin as a prognostic marker in sepsis: An observational study. Critical Care. 2005;9(6):R816–R824.
    1. Christ-Crain M., Morgenthaler N.G., et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397] Critical Care. 2006;10:R96.
    1. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 2001;22:1693–1711.
    1. Grandel U., Grimminger F. Endothelial responses to bacterial toxins in sepsis. Critical Reviews in Immunology. 2003;23:267–299.
    1. Hinson J.P., Kapas S., et al. Adrenomedullin, a multifunctional regulatory peptide. Endocrinological Reviews. 2000;21:138–167.
    1. Kedzierski R.M., Yanagisawa M. Endothelin system: The double-edged sword in health and disease. Annual Reviews in Pharmacology and Toxicology. 2001;41:851–876.
    1. Landry D.W., Oliver J.A. Insights into shock. Scientific America. 2004;290:36–41.
    1. Levin E.R. Endothelins. New England Journal of Medicine. 1995;333:356–363.
    1. Morgenthaler N.G., Struck J., et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clinical Chemistry. 2005;51:1823–1829.
    1. Muller B., Becker K.L., et al. Disordered calcium homeostasis of sepsis: Association with calcitonin precursors. European Journal of Clinical Investigation. 2000a;30:823–831.
    1. Muller B., Becker K.L., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical Care Medicine. 2000b;28:977–983.
    1. Muller B., Peri G., et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Critical Care Medicine. 2001;29:1404–1407.
    1. Muller B., Peri G., et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: Association of high decoy receptor levels with glucocorticoid administration. Journal of Leukocyte Biology. 2002;72:643–649.
    1. Papassotiriou J., Morgenthaler N.G., et al. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clinical Chemistry. 2006;52:1144–1151.
    1. Parrillo J.E. Severe sepsis and therapy with activated protein C. New England Journal of Medicine. 2005;353:1398–1400.
    1. Peters K., Unger R.E., et al. Molecular basis of endothelial dysfunction in sepsis. Cardiovascular Research. 2003;60:49–57.
    1. Pittet J.F., Morel D.R., et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Annals of Surgery. 1991;213:261–264.
    1. Polderman K.H., Girbes A.R., et al. Accuracy and reliability of APACHE II scoring in two intensive care units: Problems and pitfalls in the use of APACHE II and suggestions for improvement. Anaesthesia. 2001;56:47–50.
    1. Rongen G.A., Smits P., et al. Endothelium and the regulation of vascular tone with emphasis on the role of nitric oxide. Physiology, pathophysiology and clinical implications. Netherlands Journal of Medicine. 1994;44:26–35.
    1. Struck J., Morgenthaler N.G., et al. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides. 2005;25:1369–1372.
    1. Struck J., Tao C., et al. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369–1372.
    1. Tschaikowsky K., Sagner S., et al. Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Critical Care Medicine. 2000;28:1854–1860.
    1. Ueda S., Nishio K., et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. American Journal of Respiratory and Critical Care Medicine. 1999;160:132–136.
    1. Wagner D.P., Draper E.A., Abizanda Campos R., Nikki P., Le Gall J.R., Loirat P., Knaus W.A. Initial international use of APACHE. An acute severity of disease measure. Med Decis Making. 1984
    1. Weitzberg E., Lundberg J.M., et al. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circulatory Shock. 1991;33:222–227.

Source: PubMed

3
Prenumerera